AATD liver disease podcast series
After completion of each podcast, you will automatically be directed to the following episode in the series.
In this first episode our experts, Professor Strnad and Dr Miravitlles, discuss the incidence, impact and burden of AATD in the liver and lung. A background discussion covering the physiological role of AAT in homeostasis as well as the common comorbid conditions occurring in people with AATD is also provided. Finally, the effects of COVID-19 in people with AATD are discussed as well as early evidence for potential treatments for this population.
Alpha-1 antitrypsin deficiency (AATD) is a rare, genetic disease that predisposes individuals to an increased risk of developing lung and liver complications1,2. Liver disease associated with AATD is highly variable in severity and age of onset, and ranges from transient neonatal cholestasis and jaundice (in early childhood) to cirrhosis and liver cancer (in childhood and adulthood)1,2.
Join our experts in AATD liver disease, Professor Strnad, Professor Teckman and Dr Miravitlles for this podcast series discussing the importance of early identification, diagnosis, treatment and management of AATD.
- Bouchecareilh M. Alpha-1 Antitrypsin Deficiency-Mediated Liver Toxicity: Why Do Some Patients Do Poorly? What Do We Know So Far? Chronic Obstr Pulm Dis. 2020;7(3):172-181.
- Tanash HA, Piitulainen E. Liver disease in adults with severe alpha-1-antitrypsin deficiency. J Gastroenterol. 2019;54(6):541-548.
This content has been developed independently of the sponsor, Takeda, which has had no editorial input into the content. Medthority received educational funding from the sponsor in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.